Erasca Aktie

Erasca für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A3CU1G / ISIN: US29479A1088

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
13.08.2025 04:16:51

Erasca Narrows Loss 46% in Fiscal Q2

Erasca (NASDAQ:ERAS), a clinical-stage biotechnology company focused on developing cancer therapies targeting the RAS/MAPK pathway, released its second quarter results on August 12, 2025. The company highlighted accelerated progress for two key clinical programs and reported operating expenses well below last year, significantly narrowing its net loss. Earnings per share (GAAP) was a loss of $0.12, missing consensus estimates by a small margin. Revenue remained at zero as expected for a company without commercialized products. The quarter showed continued cost controls and clinical momentum, though future milestones remain tied to upcoming clinical trial results expected in 2026. Source: Analyst estimates for the quarter provided by FactSet. Erasca seeks to discover and develop therapies that target the RAS/MAPK signaling pathway, a critical driver of many cancers. This pathway is involved in controlling cell growth, and its mutations are found in a large number of solid tumors.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Nachrichten zu Erasca Inc Registered Shsmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Q2 Holdings Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Erasca Inc Registered Shs 2,42 13,62% Erasca Inc Registered Shs
Q2 Holdings Inc 57,00 0,88% Q2 Holdings Inc